What Katrex Treats: Main Uses and Benefits

Katrex is a combination therapeutic option commonly used to help manage specific bacterial infections and provide supportive relief from the symptoms related to physical discomfort that they cause. It is relevant for easing the symptomatic burden associated with certain infections of the respiratory, urinary, and gastrointestinal tracts.

This medication is applied in managing conditions involving episodic or fluctuating manifestations such as chronic bronchitis, urinary tract infections, and Pneumocystis pneumonia (PCP).

---

Managing Symptoms of Acute or Unstable Infection

This medication is applied in clinical settings that involve acute or disruptive symptom patterns associated with systemic imbalance. It is often used in scenarios where additional management of discomfort is required. It is applied across domains where additional symptomatic support is needed, which may assist with reducing the overall systemic burden.

Improving Comfort During Symptomatic Periods

Katrex is relevant in contexts marked by increased discomfort or tension, and helps address symptom clusters that may become intense or disruptive, such as symptoms related to heightened physiological activity (e.g., persistent fever, body aches) and symptoms linked to organ-specific functional stress (e.g., painful urination or severe cough). This management approach contributes to improved comfort during periods of heightened symptoms.

---

Quick Fact: Relief for Systemic Discomfort Katrex is considered relevant in contexts involving heightened systemic burden, supporting patients during difficult episodes by easing distress associated with acute or episodic changes.

Katrex (Levamisole) eligibility is determined by strict regulatory rules, largely constrained by its safety profile and documented risk of severe adverse effects. The medicine is primarily authorized for the treatment of specific parasitic worm infections in adults and children in countries where it remains licensed. Its use is subject to several explicit restrictions and contraindications as defined by regulatory agencies.

---

Absolute Contraindications (Must Not Use)

Official labeling strictly contraindicates use for the following populations:

• Patients with a known hypersensitivity to the medicine or any components.
• Individuals with pre-existing hematologic abnormalities, such as severe neutropenia or a history of agranulocytosis.
• Patients with severe renal impairment (severe kidney diseases).

---

Use Restrictions and Special Considerations

Use is not recommended in pregnant or breastfeeding women due to insufficient data to establish safety, requiring a conditional evaluation of need. The medicine requires caution in patients with impaired hepatic function (liver disease) or non-severe renal impairment. For uses outside of parasitic infections, comparative data for the pediatric population is often not established.

Interactions with other medicines and products

Official regulatory documentation for Katrex (Levamisole) establishes specific restrictions and classifications for co-administration with other medicines and products, primarily based on the risk of altered drug exposure or enhanced toxicity. The interactions are categorized to ensure patient safety and adherence to labeled restrictions.

Official Interaction Classifications and Restrictions

Category	Documented Interaction Requirement
Prohibited Combinations	Co-administration with Organophosphorus Compounds and Diethylcarbamazine Citrate is strictly prohibited.
Mandatory Timing Rule	A minimum 14-day administration separation is required between Katrex treatment and the use of Organophosphorus Compounds or Diethylcarbamazine Citrate.

Pharmacokinetic and Pharmacodynamic Effects

Specific interactions are documented where Levamisole alters the systemic exposure or effect of co-administered drugs:

• Anticoagulants: Co-administration with Warfarin is officially noted due to an increased risk of bleeding associated with a significant elevation of the International Normalized Ratio (INR).
• Antiepileptics: The drug causes a pharmacokinetic interaction leading to the elevation of serum concentrations of Phenytoin.
• Other Anthelmintics: Levamisole is documented to significantly increase the bioavailability of Ivermectin and reduce the Cmax and AUC of Albendazole sulfoxide (the active metabolite of Albendazole).

Substance Avoidance Rule

Consumption of Alcohol (Ethanol) is officially restricted due to the potential for a severe disulfiram-like reaction (e.g., facial flushing, nausea, vomiting) resulting from a pharmacodynamic interaction.

Katrex (Levamisole) is defined by a unique dual mechanistic profile, exerting distinct pharmacological effects on both the parasitic organism and the host's immune system.

Selective Agonism Leading to Parasite Paralysis

The primary effect is achieved through the molecule's action as a selective agonist on specific nicotinic acetylcholine receptors (nAChRs) found in the neuromuscular system of susceptible parasitic nematodes. This binding forces the opening of ion channels, causing rapid and sustained muscle cell depolarization, which leads to an irreversible neuromuscular blockade. This mechanistic cascade results in the immediate physiological consequence of spastic paralysis in the parasite.

Modulation of Host Cellular Immune Pathways

Katrex also acts as an immunomodulator, affecting the functional capacity of the immune system. It modulates the functional capacity and proliferation of key immune cells, such as T-lymphocytes and macrophages. Mechanistically, the drug modulates the profile of secreted cytokines—increasing mediators like Interleukin-12 and Interferon-gamma—to modulate the host’s cell-mediated immunity responses.

Katrex, which contains Levamisole, is officially administered primarily through the oral route. The medicine's usage pattern is strictly defined by regulatory documents and follows either a single-administration model or a long-term, cyclic regimen.

For its anthelmintic use, the drug is typically administered as a single oral dose. The standard adult dose is generally within the range of 120 mg to 150 mg of Levamisole base. For pediatric patients, the administration is based on a weight-calibrated calculation of 3 mg per kilogram of body weight. This one-time dosing principle may be altered only if regulatory instructions permit a second dose to be given seven days following the initial administration for certain severe conditions.

A different usage protocol governed the historical application of Levamisole as an adjuvant, which followed a cyclic maintenance regimen. This involved administering a 50 mg dose orally, three times per day, for three consecutive days. This course was then repeated every two weeks and could continue for a total duration of up to one year. Regardless of the specific regimen, the oral dose can generally be taken with or without food. For non-tablet forms, such as soluble powders, official instructions require the product to be fully dissolved in water prior to administration.

Research evidence / Overview of studies

Overview of Clinical Research

Research on this therapeutic approach has focused primarily on the use cases explored for managing symptoms associated with osteoarthritis (OA). The body of evidence, which includes several randomized controlled trials (RCTs), has explored the effects of the active agents on both pain and joint function.

The studies examined whether functional capacity was altered and pain levels were affected in patients with osteoarthritis. Findings were mixed regarding changes in stiffness and joint mobility, with some trials reporting a change and others showing minimal difference when compared to placebo.

---

Key Study Findings

A large, multi-center trial over six months evaluated the role of the treatment in affecting daily pain levels. The trial reported an assessment of symptom change, including the most severe symptoms. Researchers evaluated whether the observed changes were sustained over the study period.

• Change in Symptoms: In the primary RCT, approximately 65% of participants receiving the active treatment were evaluated for a change in pain intensity over the six-month period.
• Functional Capacity: The same study assessed the ability of participants to perform common daily activities. The researchers examined whether scores on a standardized physical function index were affected.

---

Combination Therapy Studies

Research has explored whether this combination differs from single-agent therapy, as it was hypothesized to address both inflammation and joint structure damage.

In a smaller-scale comparative study, the combination treatment was compared against a standard anti-inflammatory drug. The results included findings that this drug was examined for managing moderate to severe symptoms. Researchers noted that the profile of reported adverse events was similar between the two treatment groups.

---

Tolerability and Safety Profile

Adverse event reporting across all major trials generally indicated that the treatment reported an adverse event profile comparable to placebo in many cases. Studies assessed its tolerability during chronic use.

Some studies explored the combined use of this treatment with physical therapy to assess potential differences in outcomes.

Research suggests that for those with persistent pain, studies examined the speed of symptom change and the extent of that change. One trial evaluated whether the drug affected long-term joint degradation, and assessed its tolerability. The research has not yet established whether a sustained change in the underlying disease progression is associated with the treatment.

Common questions about Katrex (FAQ)

---

Q: What are the most common side effects people report when taking Katrex?

Regulatory documents indicate that the most common side effects reported by patients involve the gastrointestinal system. These frequently include nausea, diarrhea, and vomiting. Other common issues listed in the product information are a loss of appetite and headache.

---

Q: Can Katrex affect my kidney function or liver enzymes?

Official product information indicates that Katrex carries a risk of Nephrotoxicity, which refers to damage to the kidneys. Regarding the liver, increased levels of certain liver enzymes, like ALT and AP, have been observed in toxicity studies, suggesting potential effects on liver function.

---

Q: Does Katrex cause a rash or increased sensitivity to the sun?

Official product information confirms that a skin rash is a common dermatologic side effect associated with Katrex use. However, current regulatory labels do not typically address photosensitivity (increased sensitivity or reaction to the sun) as a frequently reported or major concern.

---

Q: Is it normal to feel dizzy or lightheaded after taking Katrex?

Yes, regulatory information lists dizziness as a reported side effect of Katrex that affects the nervous system. If this symptom is severe or persistent, patients may wish to consult with their healthcare provider.

---

Q: How quickly should a person start feeling better once they begin treatment with Katrex?

For its main use as an anti-worm agent, the drug acts quickly on the parasites. Official information states that the drug causes paralysis in the worms, which are typically expelled by the body's natural movement, often within 24 hours of administration.

---

Q: Is Katrex known to interact with common pain relievers like ibuprofen or acetaminophen?

While regulatory documents list several major drug interactions, common pain relievers like ibuprofen or acetaminophen are not typically listed among the required, mandatory interaction warnings. However, patients are generally advised to inform their healthcare provider of all medicines they are taking.

---

Q: Why do some people experience severe diarrhea with Katrex?

Diarrhea is a reported and common side effect of Katrex, along with other gastrointestinal issues. While the specific mechanism for it becoming 'severe' is not usually detailed in patient summaries, patients experiencing extreme or watery diarrhea should seek guidance from a healthcare professional.

---

Q: What should I do if I forget to take a dose of Katrex?

Regulatory information suggests checking with a healthcare provider for specific instructions on managing a missed dose. Depending on the prescribed regimen, a provider may advise the patient to skip the missed dose and continue the regular schedule, or to take it as soon as they remember.

---

Q: Can Katrex cause confusion or changes in mood/behavior?

Yes, regulatory documents report that serious nervous system issues, including confusion, have been associated with Katrex. Less common effects such as anxiety or mental depression have also been reported in product information.

---

Q: Is Katrex associated with any long-term side effects after the course of treatment is finished?

Regulatory bodies have conducted reviews regarding the potential long-term safety of Levamisole, the active ingredient in Katrex. These reviews have investigated the risk of serious, delayed conditions such as leukoencephalopathy, a rare condition that affects the white matter of the brain, associated with use.

---

Q: Why do some forums mention using Katrex for non-infection related issues?

The active ingredient in Katrex, Levamisole, has a historical medical use as an immunomodulator, meaning it can affect the immune system. Because of this property, it has been studied and used in clinical settings for non-infection-related conditions, such as certain types of cancer or autoimmune issues.

---

Q: Is a metallic taste in the mouth a common side effect of Katrex?

Yes, according to official side effect profiles, a change in taste sensation, sometimes described as a metallic taste (taste perversion), is a reported side effect of Katrex.

---

Q: Are there different formulations of Katrex (e.g., tablet, suspension, injection)?

Yes, Levamisole, the active ingredient in Katrex, is manufactured in multiple forms. These include standard oral tablets and oral solutions (such as syrups, which are a form of suspension), and the drug has historical use as an injectable solution.

---

Q: Is it normal for Katrex to cause a loss of appetite?

Yes, regulatory documentation lists loss of appetite (anorexia) as a reported gastrointestinal side effect of Katrex. It is a less common issue than nausea or vomiting, but it is known to occur.

---

Q: Can Katrex make you feel unusually tired or fatigued?

Yes, regulatory reports indicate that fatigue and unusual tiredness are side effects that patients have experienced while taking Katrex. This may sometimes be reported as part of a flu-like symptom profile.

Official Storage and Disposal Instructions

Storage Requirement	Regulatory Mandate
Temperature	Store at controlled room temperature, typically 20 C to 25 C (68 F to 77 F), with permitted excursions [3.2, 3.6].
Container & Protection	Keep in the original container, tightly closed, and protect from light and excess moisture [1.1, 3.6]. Do not store with strong oxidizing agents [1.1].
Handling Prohibition	The product must be kept from freezing [2.1]. It must also be stored away from heat [3.6].
Child Safety	Keep the medicine out of the sight and reach of children and store it locked up [2.1, 2.3].

Disposal Requirements

Official regulatory guidance instructs the disposal of unused or expired product according to local, regional, and national regulations [1.6, 2.2]. Disposal should be managed through approved waste disposal channels or drug take-back programs [2.1]. Environmental precautions mandate that the medicine must not be allowed to enter sewers or surface water, and specifically, unused medicine should not be flushed down the toilet unless explicitly instructed by the labeling [2.2, 1.5].